Journal of the National Cancer Institute (J Natl Cancer Inst)

Journal PubWeight™ 19162.96‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. 2000 133.74
2 Statistical aspects of the analysis of data from retrospective studies of disease. 1959 94.48
3 The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. 1993 38.99
4 The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. 1981 25.60
5 New colorimetric cytotoxicity assay for anticancer-drug screening. 1990 23.46
6 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. 1998 22.10
7 Enchancement of the infectivity of simian virus 40 deoxyribonucleic acid with diethylaminoethyl-dextran. 1968 21.44
8 Finer structure of hepatic, intestinal and renal cells of the mouse as revealed by the electron microscope. 1950 21.24
9 Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. 1989 19.87
10 The preparation and handling of replicate tissue cultures for quantitative studies. 1951 19.07
11 Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. 2004 19.00
12 Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. 1995 18.86
13 Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. 2000 16.92
14 Gatekeeper for endometrium: the PTEN tumor suppressor gene. 2000 15.41
15 Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. 2004 14.97
16 Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. 2006 14.60
17 Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. 2000 14.43
18 What is the evidence that tumors are angiogenesis dependent? 1990 13.41
19 Ten- to fourteen-year effect of screening on breast cancer mortality. 1982 13.25
20 Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. 2005 13.00
21 Observations on the cytology and electron microscopy of hepatic cells. 1955 12.86
22 Photodynamic therapy. 1998 12.83
23 Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. 2008 12.77
24 A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. 2002 12.07
25 Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. 2008 11.93
26 Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. 2012 11.91
27 Design and endpoints of clinical trials in hepatocellular carcinoma. 2008 11.27
28 Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. 2003 11.27
29 In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. 1973 11.26
30 Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. 2009 10.91
31 A human cell line from a pleural effusion derived from a breast carcinoma. 1973 10.64
32 Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. 2004 10.61
33 Phases of biomarker development for early detection of cancer. 2001 10.37
34 Overdiagnosis in cancer. 2010 10.31
35 Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. 2013 10.30
36 Projections of the cost of cancer care in the United States: 2010-2020. 2011 10.29
37 Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. 1972 10.15
38 Immunity to methylcholanthrene-induced sarcomas. 1957 10.10
39 The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. 2006 10.06
40 Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. 2006 9.91
41 A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix. 1951 9.86
42 Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. 2003 9.68
43 Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. 2002 9.65
44 Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. 1993 9.48
45 Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. 2002 9.45
46 Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. 1991 9.39
47 Reporting recommendations for tumor marker prognostic studies (REMARK). 2005 9.38
48 Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. 2005 9.10
49 All-cause mortality in randomized trials of cancer screening. 2002 8.93
50 The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. 2005 8.90
Next 50